Skip to main content

Table 2 Median dose of temozolamide, in vivo immunologial and clinical response, duration of response and median overall survival

From: Low-dose temozolomide before dendritic-cell vaccination reduces (specifically) CD4+CD25++Foxp3+ regulatory T-cells in advanced melanoma patients

Patient ID

Median dose/cycle of induction temozolamide (mg) first 4 cycles

No. vaccinations

Median no. of cells administered 106(range)

DTH Best response after 4 or more vaccinations L/H KLH

Vitiligo

Clinical response

Response duration (months)

OS (months)

After vaccination treatments

28

1400

12

12.6

+++

+++

-

SD

9

12

None

(11.5–17)

29

1400 first 2 cycles, 700 last 2 cycles

4

7.7

PD

 

3

None

(5.4–8.6)

30

1400

5

11,9

PD

 

6

None

(11.5–14)

31

1400

8

12.6

SD

4

7

None

(11.1–15.3)

32

1400 first 3 cycles, 700 last cycle

5

8.5

PD

 

6

None

(7.5–10)

33

1400

8

8.8

+++

+++

+

SD

4

12

BIOCT

(4.9–10)

34

1400

6

10.1

PD

 

14

None

(6.9–14.5)

35

1400

17

9.4

++

SD

10

36+

antiCTLA4Ab

(6.5–10.8)

36

1400

6

9.8

+

+

SD

9

41+

antiCTLA4Ab

(8.3–13.9)

37

1400 first cycle, 700 last 3 cycles

17

7.8

++

SD

4

16

None

(5.7–10)

38

1400

11

9.3

+

PD

 

12

None

(8.1–10.8)

39

1400

5

10

PD

 

7

None

(10–10)

40

1400

5

11.3

PD

 

4

None

(10–15)

41

700

10

9.3

+++

PR

6

14

None

(5.8–10)

42

700

4

10

PD

 

4

None

(10–10)

43

700

5

10

+

+

PD

 

8

None

(9.6–13.8)

44

700

7

10

+

PD

 

10

antiCTLA4Ab

(10–10)

  1. BIOCT Biochemotherapy, anti-CTLA4Ab antibody against CTLA4, PD Progressive disease, SD Stable disease,PR Partial response, Os Overall survival, DTH Delayed-type hypersensitivity, KLH Keyhole limpet hemocyanin, L/H Lysate/homogenate, + Patients alive in December 2011.